-
ELICITING CANCER PROGRESSION RATES FOR LOCALLY/REGIONAL RECURRENT (LR) POPULATIONS USING AGGREGATE LEVEL SURVIVAL DATA: AN ILLUSTRATION FROM MELANOMA
Mar 18, 2026, 21:38 PM -
ESTIMATING HETEROGENEOUS TREATMENT EFFECTS FOR PHARMACOEPIDEMIOLOGIC STUDIES: A SCOPING REVIEW FOR CAUSAL FOREST MODELS
Mar 18, 2026, 21:38 PM -
AUTOMATING BRIEFING BOOK DEVELOPMENT FOR NICE HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS USING GENERATIVE AI
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF NEOADJUVANT AND ADJUVANT PEMBROLIZUMAB IN LOCALLY ADVANCED HEAD AND NECK CANCER
Mar 18, 2026, 21:38 PM -
A MOSAIC OF EVIDENCE: THE CLINICAL AND ECONOMIC BENEFITS OF CERAMIDE-INFUSED SKIN BARRIERS IN OSTOMY CARE
Mar 18, 2026, 21:38 PM -
TARGET TRIAL EMULATION (TTE) INFORMED BY CLINICAL TRIAL DATA: ADJUVANT NIVOLUMAB VS OBSERVATION IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER (RNSCLC) AFTER NEOADJUVANT NIVOLUMAB PLUS CHEMOTHERAPY AND SURGERY
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION IN LONG-TERM CARE RESIDENTS WITH AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE TREATED WITH BREXPIPRAZOLE
Mar 18, 2026, 21:38 PM -
LEVERAGING A NATIONAL AMBULATORY CARE CLINIC NETWORK FOR REAL-WORLD EVIDENCE: INSIGHTS FROM A LARGE US EHR DATASET
Mar 18, 2026, 21:38 PM -
A PILOT ASSESSMENT OF LLM-GENERATED SYNTHETIC COHORTS: A FIRST STEP TOWARD ROBUST SYNTHETIC CONTROL ARMS
Mar 18, 2026, 21:38 PM -
COST OF HYPERTENSION MANAGEMENT AMONG PEOPLE LIVING WITH HYPERTENSION IN SELECTED PUBLIC HOSPITALS IN ILORIN, NIGERIA
Mar 18, 2026, 21:38 PM -
DEFINING CURATIVE POTENTIAL IN EARLY-STAGE MELANOMA: WHERE PHYSICIANS AND PAYERS ALIGN AND WHERE THEY DON’T
Mar 18, 2026, 21:38 PM -
US PAYER COST-OF-CARE ANALYSIS FOR DURVALUMAB IN COMBINATION WITH ETOPOSIDE/PLATINUM VS ATEZOLIZUMAB-BASED REGIMENS IN 1L ES-SCLC SETTING
Mar 18, 2026, 21:38 PM -
CO-PAYMENT FOR ALK SUBLINGUAL IMMUNOTHERAPY TABLETS PAID BY PATIENTS ENROLLED IN A PATIENT SUPPORT PROGRAM IN BRITISH COLUMBIA
Mar 18, 2026, 21:38 PM -
REAL-WORLD UTILIZATION SHIFTS AND AI/NLP-DERIVED CLINICAL DRIVERS OF BIOLOGIC-TO-BIOSIMILAR SWITCHING IN INFLAMMATORY BOWEL DISEASE (IBD)
Mar 18, 2026, 21:38 PM -
METHODOLOGICAL DIVERGENCE AND POLICY IMPACT OF HTAS FOR IMMUNE CHECKPOINT INHIBITORS IN NSCLC
Mar 18, 2026, 21:38 PM -
MARKOV MODEL-BASED COST-UTILITY ANALYSIS COMPARING RANIBIZUMAB WITH PANRETINAL PHOTOCOAGULATION FOR PROLIFERATIVE DIABETIC RETINOPATHY IN INDIA
Mar 18, 2026, 21:38 PM -
RACIAL AND ETHNIC DISPARITIES IN POST-SURGICAL PAIN MANAGEMENT AMONG PATIENTS UNDERGOING ORTHOPEDIC SURGERY IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
INCORPORATING DYNAMIC DRUG PRICING IN US COST-EFFECTIVENESS MODELS: A HYPOTHETICAL SIMULATION STUDY
Mar 18, 2026, 21:38 PM -
PATIENT CHARACTERISTICS AND UTILIZATION OF ADALIMUMAB-BWWD IN THE US DEPARTMENT OF VETERANS AFFAIRS POPULATION
Mar 18, 2026, 21:38 PM -
REAL-WORLD ECONOMIC OUTCOMES ASSOCIATED WITH SWITCHING BETWEEN BIOLOGICS AND BIOSIMILARS IN IMMUNE-MEDIATED INFLAMMATORY DISEASES
Mar 18, 2026, 21:38 PM
